Shanghai Changzheng Hospital
Clinical trials sponsored by Shanghai Changzheng Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough prostate cancer: experimental combo targets resistant tumors Results expected Dec 2026 (estimated)
- Quantum leap in cancer detection: AI blood test could slash unnecessary biopsies Results expected Dec 2026 (estimated)
- Can enzyme pills fix blood sugar in pancreatitis patients? Results expected Dec 2026 (estimated)
- Could a supplement boost prostate cancer treatment? Results expected Jan 2027 (estimated)
- New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease Results expected Apr 2027 (estimated)
-
Can reprogrammed immune cells take on hard-to-treat kidney cancer?
Cure PausedThis early-phase trial is testing a therapy called anti-CD70 CAR-T cells in people with advanced kidney cancer that has not responded to standard treatments. The approach involves taking a patient's own immune cells, engineering them in a lab to recognize a protein called CD70 on…
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Can an antimalarial drug boost immunotherapy against colorectal cancer?
Disease control OngoingThis trial tests whether adding dihydroartemisinin, a malaria drug, to a standard chemotherapy plus immunotherapy combo can shrink or eliminate colorectal tumors in people whose cancer has not spread widely or has returned after first-line treatment. The goal is to make surgery m…
Phase 2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an immunotherapy cocktail make rectal tumors disappear before surgery?
Disease control OngoingThis phase 2 trial tests whether giving pembrolizumab, bevacizumab, and chemotherapy before surgery can improve outcomes for people with a common type of locally advanced rectal cancer. The cancer must be microsatellite stable, which typically does not respond well to immunothera…
Phase 2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody combo aims to control hard-to-treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Engineered immune cells take on hard-to-treat prostate cancer
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…
Phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Front vs back surgery: which is better for stiff spine condition?
Disease control OngoingThis study compares two surgical approaches for severe ossification of the posterior longitudinal ligament (OPLL), a condition where a ligament in the spine hardens and presses on the spinal cord. One surgery (ACAF) goes through the front of the neck to remove the hardened ligame…
Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood DNA fragments and MRI join forces to spot hidden prostate cancer
Diagnosis PausedThis trial tests whether combining a blood test that analyzes DNA fragments (cfDNA) with MRI scans can better detect prostate cancer in men with borderline PSA levels (4–10 ng/mL). Researchers aim to build a prediction model that could reduce unnecessary biopsies. The study invol…
Sponsor: Shanghai Changzheng Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC